Biosimilars Drug Pricing Labelling 
STAT
OCTOBER 2, 2024
The effort comes after CVS Health and Cigna — which own CVS Caremark and Express Scripts, respectively — launched subsidiaries that are striking “co-manufacturing” deals with companies that make biologic medicines and lower-cost versions known as biosimilars.
STAT
NOVEMBER 28, 2022
A hotly contested provision of a federal law designed to speed copycat drugs to market and foster competition saved Medicare $1.5 billion from 2015 to 2020 — or nearly 5% of the $30.2 billion spent by the health care program — on just five medicines during that period, according to a new analysis.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Channels
OCTOBER 3, 2023
Since I published the article below in July 2023 , there have been three notable market develpoments: IQVIA has reported that as as of mid-2023, there was almost no adoption of Amgen's Amjevita, the first Humira biosimilar. Boehringer-Ingelheim launched an unbranded, low WAC version of its interchangeable biosimilar.
Safe Biologics
DECEMBER 3, 2023
ASBM and GaBI Webinar Examines Policy Challenges to Interchangeable Biosimilars On November 30, ASBM and the Generics and Biosimilars Initiative (GaBI) hosted I nterchangeable Designation for Biosimilars- Ensuring Continuity of Patient Care: Upholding Interchangeability Status for Biosimilars.
Safe Biologics
NOVEMBER 12, 2023
6 “The Biosimilar Red Tape Elimination Act”, which would prevent the HHS Secretary from requiring switching studies in order for a biosimilar to be deemed “interchangeable” Under U.S. state law, only biosimilars which are interchangeable may be substituted by a pharmacist without contacting the prescriber.
FDA Law Blog: Biosimilars
APRIL 2, 2024
Perhaps unsurprisingly given the extraordinary focus on drug pricing in the last decade, generic competition—FDA’s only real way to have an effect on drug pricing—tops this year’s list. In the second category—limiting blockades to marketing—are efforts to limit blocking exclusivities and induced infringement liability.
Safe Biologics
DECEMBER 6, 2023
prescribers have high confidence in the safety and efficacy of biosimilars, a majority (58%) oppose third-party switching of a patient’s biologic medicine for non-medical (e.g. state law, only biosimilars which are interchangeable may be substituted by a pharmacist without contacting the prescriber. and worldwide.”
Expert insights. Personalized for you.
294 
Let's personalize your content